Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.

Abstract excerpt

Lung cancer is a leading cause of cancer-related mortality worldwide, accounting for approximately 13% of all diagnoses. Non-small cell lung cancer (NSCLC) comprises 85% of lung cancer cases, with recent genetic profiling revealing the critical role of driver mutations in its pathogenesis. Advances in molecular stratification have redefined NSCLC classification, enabling targeted therapeutic approaches based on...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Approval
• Share to Molecular Targeted Therapy